> Again, it was just an assumption that vaccines would be "safe enough", despite no mRNA vaccine having ever been rolled out at scale.
Why is this a criterium we should pay attention to? If you never roll anything out, you'll never have data about a roll out. So instead we do studies and statistical analyses. Are you aware of any studies that "normal"/previous vaccines had to go through, which mRNA COVID vaccines did not? If so, could you please share them?
I'm not aware of any approved vaccine where the observation period in the RCT was a mere four months and the control group was vaccinated thereafter. If there is another such vaccine, I would be hesitant to take that one as well.
There's no controlled experiment to suggest that mRNA vaccines provide a survival advantage to a healthy individual. The brief RCTs certainly don't support it. The increased cardiac risk, small as it may be, may well put the vaccine into negative benefit territory for some, but we'll probably never know for sure, because none of our data is robust enough to draw such conclusions.
Why is this a criterium we should pay attention to? If you never roll anything out, you'll never have data about a roll out. So instead we do studies and statistical analyses. Are you aware of any studies that "normal"/previous vaccines had to go through, which mRNA COVID vaccines did not? If so, could you please share them?